ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Core Insights - Lavie Bio is a leader in the ag-biologicals industry with a strong pipeline of microbiome-based products, transferring key assets to ICL, including its core team, BDD technology platform, microbial bank, and most development programs [1][2][3] - The transaction is a result of over two years of collaboration between ICL and Lavie Bio, aimed at developing bio-stimulant solutions for crops under abiotic stress [2][3] - The integration of Lavie Bio into ICL is expected to significantly advance the ag-biologicals field and drive innovation in agriculture [3] Company Overview - Lavie Bio, a subsidiary of Evogene Ltd., focuses on enhancing food quality and agricultural productivity through microbiome-based products, utilizing a proprietary computational predictive platform powered by Evogene's MicroBoost AI technology [4] - Evogene Ltd. is a computational biology company that aims to revolutionize life-science product development through advanced technologies, including MicroBoost AI, ChemPass AI, and GeneRator AI, which are designed for discovering and developing products based on microbes, small molecules, and genetic elements [6]